Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd
APLLTD![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
32.77 | 4.28 | 1.05% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,173.11 | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,256.93 | 6,323.27 | ||||||||||
Raw Materials | 877.07 | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 1,857.92 | 5,333.65 | ||||||||||
Power & Fuel Cost | 58.89 | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | 173.37 | |||||||||||
Employee Cost | 472.85 | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | 1,446.29 | |||||||||||
Selling & Administrative Expenses | 507.40 | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | 1,543.70 | |||||||||||
Operating & Other expenses | 243.09 | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | 274.96 | |||||||||||
EBITDA | 1,013.81 | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 960.69 | 989.62 | ||||||||||
Depreciation/Amortization | 72.21 | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 272.67 | 275.53 | ||||||||||
PBIT | 941.60 | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 688.02 | 714.09 | ||||||||||
Interest & Other Items | 5.43 | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 56.19 | 54.98 | ||||||||||
PBT | 936.17 | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 631.83 | 659.11 | ||||||||||
Taxes & Other Items | 216.12 | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 16.01 | 29.18 | ||||||||||
Net Income | 720.05 | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 615.82 | 629.93 | ||||||||||
EPS | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 31.33 | 32.05 | ||||||||||
DPS | 3.50 | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 11.00 | 8.00 | ||||||||||
Payout ratio | 0.09 | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.35 | 0.25 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alembic Pharmaceuticals Ltd | 33.52 | 4.28 | 1.05% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare APLLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Kotak Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.8768% | Percentage of the fund’s portfolio invested in the stock 2.32% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/82 (+1) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.7544% | Percentage of the fund’s portfolio invested in the stock 1.89% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/69 (-23) |
Axis Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8262% | Percentage of the fund’s portfolio invested in the stock 0.73% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 38/134 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
APLLTD has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 1.05%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.48 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹11.00
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 16, 2020
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip slipped 1.50% to settle at Rs 1,100.55 on Friday, 23 August 2024. Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication. Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. Alembic has a cumulative total of 211 ANDA approvals (183 final approvals and 28 tentative approvals) from USFDA,' the company said in a statement. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dabigatran Etexilate Capsules, 110 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Dabigatran Etexilate Capsules 110 mg are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. Alembic has a cumulative total of 211 ANDA approvals (183 final approvals and 28 tentative approvals) from USFDA. Powered by Capital Market - Live
Steel Authority of India Ltd, IFCI Ltd, Coffee Day Enterprises Ltd and Orient Cement Ltd are among the other losers in the BSE's 'A' group today, 09 August 2024.Alembic Pharmaceuticals Ltd lost 6.26% to Rs 1138.15 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 36635 shares were traded on the counter so far as against the average daily volumes of 37981 shares in the past one month.Steel Authority of India Ltd crashed 5.96% to Rs 129.3. The stock was the second biggest loser in 'A' group.On the BSE, 47.15 lakh shares were traded on the counter so far as against the average daily volumes of 19.79 lakh shares in the past one month.IFCI Ltd tumbled 5.60% to Rs 70.96. The stock was the third biggest loser in 'A' group.On the BSE, 53.78 lakh shares were traded on the counter so far as against the average daily volumes of 86.01 lakh shares in the past one month.Coffee Day Enterprises Ltd pared 5.28% to Rs 46.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 8.46 lakh shares were traded on the counter so far as against the average daily volumes of 2.93 lakh shares in the past one month.Orient Cement Ltd shed 5.26% to Rs 331.4. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.79 lakh shares were traded on the counter so far as against the average daily volumes of 2.09 lakh shares in the past one month.Powered by Capital Market - Live
Net profit of Alembic Pharmaceuticals rose 11.70% to Rs 134.71 crore in the quarter ended June 2024 as against Rs 120.60 crore during the previous quarter ended June 2023. Sales rose 5.09% to Rs 1561.73 crore in the quarter ended June 2024 as against Rs 1486.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1561.731486.15 5 OPM %15.1613.37 - PBDT226.07195.94 15 PBT157.03129.76 21 NP134.71120.60 12 Powered by Capital Market - Live
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Soriatane Capsules, 10 mg, 17.5 mg, and 25 mg, of Stiefel Laboratories, Inc. (Stiefel). Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Refer label for a detailed indication. Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg have an estimated market size of US$ 21 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 212 ANDA approvals (184 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Soriatane Capsules of Stiefel Laboratories, Inc. Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Acitretin Capsules USP has an estimated market size of US$ 21 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 212 ANDA approvals (184 final approvals and 28 tentative approvals) from US FDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world. The company reported 16.78% increase in consolidated net profit to Rs 178.21 crore on 7.85% rise in revenue from operations to Rs 1,516.98 in Q4 FY24 over Q4 FY23. Powered by Capital Market - Live
Alembic Pharma Gets US FDA Nod For Generic Cancer Drug
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/bloombergquint%2F2024-08%2F20490243-e42d-43e0-a015-e054cf46edd1%2Fnappy-uZfEs-OW9OQ-unsplash.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 9.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.74% to 1.66%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.17%